RNA, U6 small nuclear 1082, pseudogeneGenealiases: []
Q-omics provides the consensus-scored RNU6-1082P profile across patient tissues and cancer cell-line models. RNU6-1082P expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, RNU6-1082P is differentially expressed in 3, with the highest sampling consensus in STAD. Additionally, RNU6-1082P RNA expression shows 10,613 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight LUAD, STAD, and LSCC as cancer lineages where RNU6-1082P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RNU6-1082P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RNU6-1082P survival associations across molecular data types. RNU6-1082P RNA expression shows survival associations in the most cancer types (16). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RNU6-1082P RNA expression–survival associations across cancer types. High RNU6-1082P expression shows unfavorable associations in CHOL, STAD, KIRC, CESC and THCA, but favorable associations in LUAD. The LUAD Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .004). Together, the overview and detailed table identify LUAD as the clearest survival context for RNU6-1082P RNA expression.
This table summarizes RNU6-1082P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for RNU6-1082P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RNU6-1082P shows lower tumor expression in LUSC and KICH and higher tumor expression in STAD. The STAD box plot shows higher RNU6-1082P RNA expression in tumor versus normal tissue (log2 FC = +0.669, t-test p < 0.001).
This table shows molecular features associated with RNU6-1082P in patient tissues and cancer cell lines. In patient samples, RNU6-1082P shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set.
